Press Releases

Emergent BioSolutions Provides Preliminary 2011 Financial Results and Provides Guidance for 2012

...

Read More

Emergent Announces Plans for TRU-016 Program Following Termination of Collaboration with Abbott

...

Read More

Emergent Initiates Phase 2 Study of TRU-016 in Combination with Bendamustine in Patients with Relapsed Chronic Lymphocytic Leukemia

...

Read More

Emergent BioSolutions Announces Fuad El-Hibri to Retire as CEO, Remain as Executive Chairman of the Board of Directors Focused on Corporate Strategy and M&A Opportunities

...

Read More

Emergent BioSolutions to Participate in January 2012 Investor Conferences

...

Read More

Emergent BioSolutions Announces Acceptance of Four TRU-016 Abstracts for Presentation at 2011 American Society of Hematology Annual Meeting

...

Read More

Emergent BioSolutions Receives Orphan Drug Designation for Its TRU-016 Protein Therapeutic for the Treatment of Chronic Lymphocytic Leukemia

...

Read More

Emergent BioSolutions Initiates Pivotal Clinical Trial Evaluating a Three-Dose BioThrax Regimen for Post-Exposure Prophylaxis

...

Read More

Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2011

...

Read More

Emergent BioSolutions to Participate in November 2011 Investor Conferences

...

Read More

Emergent BioSolutions to Release Third Quarter 2011 Financial Results and Conduct a Conference Call on November 3, 2011

...

Read More

Emergent BioSolutions Receives Award to Supply 44.75 Million Doses of BioThrax to U.S. Government over Five Years

...

Read More